基于多发性骨髓瘤肾损害早期诊断策略的研究进展  

Research about Early Diagnosis Strategy in Renal Impairment Due to Multiple Myeloma

作　　者：张蕊 刘金彦[2] 

机构地区：[1]济宁医学院临床医学院,山东 济宁 [2]济宁市第一人民医院肾内科,山东 济宁

出　　处：《临床医学进展》2022年第5期4770-4775,共6页Advances in Clinical Medicine

摘　　要：多发性骨髓瘤(Multiple Myeloma, MM)是浆细胞恶性增殖性疾病,因为骨髓中浆细胞的异常增殖,且伴有单克隆免疫球蛋白或轻链的过度产生,造成了多器官受损,其中肾损害是其常见的临床表现。多发性骨髓瘤患者致死率、致残率高,存活期短,而伴肾损害的尤甚,故防治急慢性的肾损害是骨髓瘤患者整体预后的关键。骨髓瘤肾损害的诊断指标有多种,当前评价骨髓瘤患者的肾功能常用临床指标是血肌酐,但其不太灵敏,当发生轻微肾损害时,血肌酐指标尚未变动,而骨髓瘤导致的肾损害需快速、早诊断。因此,本文主要是对多发性骨髓瘤肾损害早期诊断指标的检测及现阶段研究进展进行阐述。Multiple Myeloma is plasma cells malignant hyperplastic disease. The multiplication abnormal of plasma cells in bone marrow and excessive production of the monoclonal immunoglobulin or Light chain, cause multiple organ damage. Renal impairment is the common clinical manifestations. Pa-tients with multiple myeloma have high fatality rate and morbidity, especially these patients with renal damage. Prompt and effective treatment can improve the overall prognosis of these patients with renal damage. There are many diagnostic indicators of myeloma renal damage diagnosis index, the common target is serum creatinine, but it is not too sensitive. Because serum creatinine index has not changed when renal damage is slight. However, MM with Kidney damage requires quick di-agnosis in the early time. This article reviews the possible diagnostic indicators and previous re-search progress of renal damage based on Multiple Myeloma.

关 键 词：多发性骨髓瘤 肾损害 MICRORNA 血清胱抑素C 血管细胞黏附因子-1 

分 类 号：R733.3[医药卫生—肿瘤]